Crossject announced that it has been awarded ?6.9 million in public funding as part of the "i-Démo" call for projects under the France 2030 Plan, operated by Bpifrance on behalf of the French Government. The France 2030 plan aims at supporting French companies that demonstrate exceptional potential for growth and innovation. It will support Crossject's innovative project to accelerate the development of its ZENEO Epinephrine needle-free autoinjector, and save lives thanks to this new emergency treatment administered by a patient or its family in the event of severe allergic reactions (anaphylactic shock).

The project, which runs until 2026, consists of subsidies for 60% of the total, and of subsidized loans for the remainder, with an initial payment of EUR 1.7 million scheduled in the coming weeks, a development milestone of 4 million euros expected in August 2025 and the balance at the end of the project in 2026. The product is expected to generate cumulative sales of around EUR 1 billion by 2032 for Crossject and its distributors, contribute to the creation of more than 160 jobs over the period 2024-2032, and support Crossject's actions to reduce the carbon footprint of ZENEO Epinephrine. The project was also certified by the French cluster PMT.

The drug solution in ZENEO Epinephrine is innovative and patented by Crossject (FR3095122B1, WO2020212381A1). Importantly, it relies on a proprietary sulfite-free formulation. Sulfites are used as preservatives in many current products and are known to trigger intolerance, or even allergy, which can lead to an anaphylactic shock, the very event that needs to be treated.

Moreover, Crossject?s new solution shows superior shelf-life performance and should enable a longer stability period compared to current drugs. The formulation developed by Crossject should hence not only reassure patients about the risk of drug-related allergy, but also meet their strong need for a simpler device that can be kept for longer. In addition, the ZENEO auto-injector ensures a simple, complete injection of the entire dose in just a few milliseconds, with negligible residual volume.

This should be a significant advantage over needle-based systems on the market. Crossject plans to file marketing authorization applications for ZENEO® Epinephrine in 2026 with regulatory authorities in Europe and the United States.